Roswell Park’s early phase oncology research program is among the largest in New York State.

We offer a vast portfolio of options — accommodating all cancer types, for wherever the patient is in the spectrum of their disease — newly diagnosed, in remission, or facing recurrence.

What Sets Us Apart

- **Innovative new approaches** including angiogenesis inhibitors, novel targets and immunotherapies such as cancer vaccines, antibody therapy, cellular therapy and immune response modifiers.

- **Clinical Research Center**, a dedicated 7-bed, 10-chair clinical space to provide highest level of patient safety, monitoring and protocol adherence.

- **Streamlined evaluation process**. Within two weeks patients are seen by an oncologist from our team and presented with therapeutic options.

- **Lodging assistance** for out-of-town patients who need an affordable place to stay during their treatment.

- **On-site pharmacist** from the Investigational Drug Service to consult with patients, family members and staff as needed.

- **Collaboration with primary care team**. Your patient will remain your patient. Partnering with us allows access to options and resources that may impact your patient’s prognosis in a meaningful way.
Meet the Team

1. Igor Puzanov, MD, MSCI, FACP
   Director, Early Phase Clinical Trials Program
   Co-Leader, CCSG Experimental Therapeutics Program

2. Grace Dy, MD
   Associate Professor of Oncology
   Division Chief, Thoracic Oncology

3. Tong Dai, MD
   Associate Professor of Oncology
   Thoracic Oncology

4. Christos Fountzilas, MD
   Assistant Professor of Oncology
   Gastrointestinal Oncology

5. Shipra Gandhi, MD
   Assistant Professor of Oncology
   Breast Oncology

Contact Us

Dawn DePaolo, RN, MSNL, CCRP
Clinical Research Administrator
716-845-3165

Patients may self-refer by calling
1-800-ROSWELL
(1-800-767-9355)

Our Portfolio of Studies

Roswell Park’s Early Phase Clinical Trials involve the latest modalities and novel agents for all solid tumors.

A sampling of therapies available as a single agent or in combination with standard of care are listed to the right:

### Immunotherapy
- Anti-PD1
- Anti-PD-L1
- Anti-CTLA4
- Cancer vaccines
- Cellular therapy
- Engineered T-cell therapy
- Mutant IL-2
- Oncolytic virus

### Targeted Therapy
- Antibody drug conjugates
- Antibody targeting radiation
- Histone deacetylase inhibitor
- IDO1 inhibitors
- KRAS targeting G12c inhibitors
- PI3K-MTOR targeting
- RET targeting inhibitors
- SRC kinase and tubulin polymerization inhibitor

Elm & Carlton Streets | Buffalo, NY 14263